Q-Switched Nd:YAG in Macular Amyloidosis

Macular Amyloidosis Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00353392
• Other study ID #: src-ost-1359
• Status: Completed
• Phase: Phase 1
• First received: July 17, 2006
• Last updated: December 18, 2013
• Start date: March 2006
• Est. completion date: August 2006

Study information

• Verified date: November 2006
• Source: hahid Beheshti University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: Iran: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Q-Switched Nd:YAG Laser therapy are effective in reduction of Cutaneous macular amyloidosis.

Description:

We treat the macular amyloidosis cases by Q-Switched Nd:YAG Laser and compare the before and after treatment situation by the photos and colorimetric assessment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 2006
• Est. primary completion date: July 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Macular amyloidosis confirmed cases

Exclusion Criteria:

• Pregnancy and breast feeding

• Over 18 years old

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Amyloidosis
• Macular Amyloidosis

Intervention

Device:
• Laser Therapy

Locations

Country	Name	City	State
Iran, Islamic Republic of	Skin Research Center, Shaheed Beheshti Medical University	Tehran

Sponsors (1)

Lead Sponsor	Collaborator
hahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual and colorimetric assessment